Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
GNB3 2784 OLANZAPINE CHEMBL715 PharmGKB
GNB3 2784 SIMVASTATIN CHEMBL1064 PharmGKB
GNB3 2784 CERIVASTATIN CHEMBL1477 PharmGKB
GNB3 2784 LOVASTATIN CHEMBL503 PharmGKB
GNB3 2784 HYDROCHLOROTHIAZIDE CHEMBL435 PharmGKB

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
GNB3 rs5443 C risperidone "dosage","efficacy" yes Allele C is not associated with response to risperidone in people with Schizophrenia as compared to allele T. 18308786 982022015
GNB3 rs5443 TT sildenafil efficacy yes Genotype TT is associated with increased response to sildenafil in people with Erectile Dysfunction as compared to genotypes CC + CT. 12576843 699639234
GNB3 rs5443 CT sumatriptan efficacy yes This is in Whites(Germans). There were not enough TT people for a significant conclusion. Genotype CT is associated with increased response to sumatriptan in people with Cluster Headache as compared to genotype CC. 17361120 655385715
GNB3 rs45476395 T sertraline efficacy no No significant association between this variant and changes in HDRS score during 6 weeks of sertraline treatment. Variant referred to as A657T in the paper. Allele T is not associated with response to sertraline in people with Depressive Disorder, Major as compared to allele A. 30324302 1450931941
GNB3 rs5443 TT methadone "dosage","metabolism/PK" yes Genotype TT is not associated with increased dose of methadone in people with Heroin Dependence as compared to genotype CC. 21902500 827816353
GNB3 rs5443 CC antidepressants efficacy no Genotype CC is not associated with response to antidepressants in people with Depressive Disorder, Major as compared to genotypes CT + TT. 23733030 982028793
GNB3 rs5443 CC + CT antidepressants efficacy yes Genotypes CC + CT are associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to genotype TT. 23733030 982028800
GNB3 rs2301339 GG atenolol efficacy yes Women with the GG genotype had greater decreases in diastolic blood pressure (DBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to AA homozygotes. No significant results were seen in men (data not shown). Genotype GG is associated with increased response to atenolol in women with Essential hypertension as compared to genotype AA. 20235788 982044983
GNB3 rs11064426 AA atenolol efficacy yes Women with the AA genotype had greater decreases in diastolic blood pressure (DBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to CC homozygotes. No significant results were seen in men (data not shown). Genotype AA is associated with increased response to atenolol in women with Essential hypertension as compared to genotype CC. 20235788 982044975
GNB3 rs2301339 GG atenolol efficacy yes GG homozygotes had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to A allele carriers. No significant results were seen for diastolic blood pressure. Genotype GG is associated with increased response to atenolol in people with Essential hypertension as compared to genotypes AA + AG. 20235788 982044931
GNB3 rs5443 CT + TT clonidine efficacy yes Exclusively male participants. Increased response for T allele carriers was shown by: greater reductions in plasma norepinephrine levels, systolic blood pressure and total peripheral resistance, greater increases in serum growth hormone and electromechanical systole (QS2c) duration, and slowing of pulse wave velocity, as compared to those with the CC genotype. Changes in these measurements were assessed between baseline and a varied number of hours (indicated in the study parameters). Genotypes CT + TT are associated with increased response to clonidine in healthy individuals as compared to genotype CC. 12844135 982034073
GNB3 rs11064426 AA atenolol efficacy yes AA homozygotes allele had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to CC homozygotes. No significant results were seen for diastolic blood pressure. Genotype AA is associated with increased response to atenolol in people with Essential hypertension as compared to genotype CC. 20235788 982044923
GNB3 rs2301339 GG atenolol efficacy yes Women with the GG genotype had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to carriers of the A allele. No significant results were seen in men (data not shown). Genotype GG is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes AA + AG. 20235788 982044957
GNB3 rs11064426 AA atenolol efficacy yes Women with the AA genotype had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to carriers of the C allele. No significant results were seen in men (data not shown). Genotype AA is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes AC + CC. 20235788 982044949
GNB3 rs5443 TT hydralazine / isosorbide dinitrate efficacy yes Fixed-dose combination of isosorbide dinitrate and hydralazine in A-HeFT (African American Heart Failure Trial) improved outcomes in TT genotype, but did not improve outcomes in CC or CT. Outcomes were composite score (death, hospital stay for heart failure), quality of life, and event-free survival. Genotype TT is associated with increased response to hydralazine / isosorbide dinitrate in people with Heart Failure as compared to genotypes CC + CT. 25306451 1447520644
GNB3 rs5443 TT telmisartan efficacy yes Genotype TT is associated with decreased response to telmisartan in people with Essential hypertension as compared to genotypes CC + CT. 26712426 1447680321
GNB3 rs5441 GG sertraline efficacy yes Patients with the GG genotype were significantly more likely to respond to sertraline than those with the AA or AG genotypes. Response was defined by achieving at least a 50% reduction in baseline HDRS score during six weeks of sertraline treatment. Variant referred to as A-350G in the paper. Genotype GG is associated with increased response to sertraline in people with Depressive Disorder, Major as compared to genotypes AA + AG. 30324302 1450931954
GNB3 rs5443 T atenolol efficacy no No significant association between this variant and response to atenolol or metoprolol, as measured by changes in heart rate, in black or white patients. Allele T is not associated with response to atenolol or metoprolol in people with Tachycardia as compared to allele C. 31090079 1451107275
GNB3 rs5443 TT bumetanide efficacy yes TT homozygotes had reduced urinary excretion of sodium chloride and calcium, and reduced volume of urinary excretion, compared to CC homozygotes, during the 24 hours after drug administration. Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC. 20877298 982045336
GNB3 rs5443 CT + TT clonidine efficacy no Exclusively male participants. No significant differences in change of diastolic blood pressure, heart rate, salivary flow or sedation over time were seen between the genotypes. Genotypes CT + TT are not associated with response to clonidine in healthy individuals as compared to genotype CC. 12844135 982034360
GNB3 rs5443 CC atenolol efficacy yes CC homozygotes had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to T allele carriers. No significant results were seen for diastolic blood pressure. Genotype CC is associated with increased response to atenolol in people with Essential hypertension as compared to genotypes CT + TT. 20235788 982044907
GNB3 rs5443 CT + TT clonidine efficacy yes Carriers of the T allele were more likely to respond to clonidine treatment as compared to CC homozygotes. Responders were defined as those with a 20% decrease in body weight and a 20% increase in urine sodium volume after 3 months of treatment. Genotypes CT + TT are associated with increased response to clonidine in people with Liver Cirrhosis as compared to genotype CC. 20833658 982044485
GNB3 rs5443 CC atenolol efficacy yes Women with the CC genotype had greater decreases in diastolic blood pressure (DBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to TT homozygotes. No significant results were seen in men (data not shown). Genotype CC is associated with increased response to atenolol in women with Essential hypertension as compared to genotype TT. 20235788 982044965
GNB3 rs5443 CC atenolol efficacy yes Women with the CC genotype had greater decreases in systolic blood pressure (SBP) after 4 weeks and 8 weeks of treatment with atenolol, as compared to carriers of the T allele. No significant results were seen in men (data not shown). Genotype CC is associated with increased response to atenolol in women with Essential hypertension as compared to genotypes CT + TT. 20235788 982044939
GNB3 rs5443 TT amlodipine efficacy yes As measured by reduction in diastolic blood pressure Genotype TT is not associated with response to amlodipine in people with Essential hypertension as compared to genotypes CC + CT. 26712426 1447680330
GNB3 rs5443 CC sibutramine efficacy yes Patients with the CC genotype and treated with sibutramine experienced greater weight loss than patients with the CT or TT genotypes. The authors note that the study was underpowered to adequately analyze effects of the TT genotype. Genotype CC is associated with increased response to sibutramine in people with Obesity as compared to genotypes CT + TT. 12893983 1450809598